Excessive opioid use and the development of chronic migraine

Pain

Volumn 142, Issue 3, 2009, Pages 179-182

  Bigal, Marcelo E ^a,b   Lipton, Richard B ^b,c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; BOTULINUM TOXIN; OPIATE;

CHRONIC PAIN; DISEASE EXACERBATION; DRUG USE; HEADACHE; HUMAN; PAIN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; TRANSFORMED MIGRAINE;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; HUMANS; INCIDENCE; MIGRAINE DISORDERS; PRESCRIPTIONS; RISK ASSESSMENT;

EID: 61849147927     PISSN: 03043959     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pain.2009.01.013     Document Type: Review

References (39)

1. Bahra A., Matharu M.S., Buchel C., Frackowiak R.S., and Goadsby P.J. Brainstem activation specific to migraine headache. Lancet 357 (2001) 1016-1017
2. Bahra A., Walsh M., Menon S., and Goadsby P.J. Does chronic daily headache arise de novo in association with regular use of analgesics?. Headache 43 (2003) 179-190
3. Ballantyne J.C., and Mao J. Opioid therapy for chronic pain. N Engl J Med 349 (2003) 1943-1953
4. Bigal M.E., Rapoport A.M., Sheftell F.D., Tepper S.J., and Lipton R.B. Transformed migraine and medication overuse in a tertiary headache centre - clinical characteristics and treatment outcomes. Cephalalgia 24 (2004) 483-490
5. Bigal M.E., Serrano D., Buse D., Scher A., Stewart W.F., and Lipton R.B. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 48 (2008) 1157-1168
6. Bigal M.E., Serrano D., Reed M., and Lipton R.B. Chronic migraine in the population: burden, diagnosis, and satisfaction with treatment. Neurology 71 (2008) 559-566
7. Bigal M.E., Sheftell F.D., Tepper S.J., and Rapoport A.M. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 27 (2007) 568 author reply 568-569
8. Bigal M.E., Tepper S.J., Sheftell F.D., Rapoport A.M., and Lipton R.B. Field testing alternative criteria for chronic migraine. Cephalalgia 26 (2006) 477-482
9. Boes C.J., Black D.F., and Dodick D.W. Pathophysiology and management of transformed migraine and medication overuse headache. Semin Neurol 26 (2006) 232-241
10. Caudill-Slosberg M.A., Schwartz L.M., and Woloshin S. Office visits and analgesic prescriptions for musculoskeletal pain in US: 1980 vs. 2000. Pain 109 (2004) 514-519
11. Diener H.C., Bussone G., Van Oene J.C., Lahaye M., Schwalen S., and Goadsby P.J. Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 27 (2007) 814-823
12. Dodick D.W. Debate: analgesic overuse is a cause, not consequence, of chronic daily headache. Analgesic overuse is not a cause of chronic daily headache. Headache 42 (2002) 547-554
13. Freitag F.G., Diamond S., Diamond M., and Urban G. Botulinum Toxin Type A in the treatment of chronic migraine without medication overuse. Headache 48 (2008) 201-209
14. Georgescu D., Zachariou V., Barrot M., Mieda M., Willie J.T., Eisch A.J., et al. Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 23 (2003) 3106-3111
15. Himsworth H. Bradford Hill and statistics in medicine. Stat Med 1 (1982) 301-303
16. Holland P.R., Akerman S., and Goadsby P.J. Modulation of nociceptive dural input to the trigeminal nucleus caudalis via activation of the orexin 1 receptor in the rat. Eur J Neurosci 24 (2006) 2825-2833
17. Holland P.R., and Bartsch T. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication overuse headache: findings from cerebrospinal fluid. Cephalalgia 28 (2008) 681-682
18. Katsarava Z., Schneeweiss S., Kurth T., Kroener U., Fritsche G., Eikermann A., et al. Incidence and predictors for chronicity of headache in patients with episodic migraine. Neurology 62 (2004) 788-790
19. King T., Ossipov M.H., Vanderah T.W., Porreca F., and Lai J. Is paradoxical pain induced by sustained opioid exposure an underlying mechanism of opioid antinociceptive tolerance?. Neurosignals 14 (2005) 194-205
20. Krymchantowski A.V., and Moreira P.F. Out-patient detoxification in chronic migraine: comparison of strategies. Cephalalgia 23 (2003) 982-993
21. Lipton R.B., and Bigal M.E. The epidemiology of migraine. Am J Med 118 (2005) 3S-10S
22. Lipton R.B., and Bigal M.E. Migraine: epidemiology, impact, and risk factors for progression. Headache 45 (2005) S3-S13
23. Olesen J., Bousser M.G., Diener H.C., Dodick D., First M., Goadsby P.J., et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 26 (2006) 742-746
24. Sarchielli P., Rainero I., Coppola F., Rossi C., Mancini M., Pinessi L., et al. Involvement of corticotrophin-releasing factor and orexin-A in chronic migraine and medication-overuse headache: findings from cerebrospinal fluid. Cephalalgia 28 (2008) 714-722
25. Scher A.I., Stewart W.F., Liberman J., and Lipton R.B. Prevalence of frequent headache in a population sample. Headache 38 (1998) 497-506
26. Scher A.I., Stewart W.F., Ricci J.A., and Lipton R.B. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain 106 (2003) 81-89
27. Shakir S.A., and Layton D. Causal association in pharmacovigilance and pharmacoepidemiology: thoughts on the application of the Austin Bradford-Hill criteria. Drug Saf 25 (2002) 467-471
28. Silberstein S.D. Clinical practice guidelines. Cephalalgia 25 (2005) 765-766
29. Silberstein S.D., Lipton R.B., and Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 47 (1996) 871-875
30. Steiner T.J. Lifting The Burden: the global campaign to reduce the burden of headache worldwide. J Headache Pain 6 (2005) 373-377
31. Sullivan L.E., Chawarski M., O'Connor P.G., Schottenfeld R.S., and Fiellin D.A. The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?. Drug Alcohol Depend 79 (2005) 113-116
32. Taylor F.R., and Saper J.R. Opioid tolerance or rather opioid-induced pain sensitivity. Headache 44 (2004) 839-840
33. Welch K.M., Nagesh V., Aurora S.K., and Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness?. Headache 41 (2001) 629-637
34. Wilkinson S.M., Becker W.J., and Heine J.A. Opiate use to control bowel motility may induce chronic daily headache in patients with migraine. Headache 41 (2001) 303-309
35. Yamamoto T., Nair P., Vagner J., Largent-Milnes T., Davis P., Ma S.W., et al. A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists. J Med Chem 51 (2008) 1369-1376
36. Zeeberg P., Olesen J., and Jensen R. Discontinuation of medication overuse in headache patients: recovery of therapeutic responsiveness. Cephalalgia 26 (2006) 1192-1198
37. Zeeberg P., Olesen J., and Jensen R. Probable medication-overuse headache: the effect of a 2-month drug-free period. Neurology 66 (2006) 1894-1898
38. Zwart J.A., Dyb G., Hagen K., Svebak S., and Holmen J. Analgesic use: a predictor of chronic pain and medication overuse headache - the Head-HUNT Study. Neurology 61 (2003) 160-164
39. Zwart J.A., Dyb G., Hagen K., Svebak S., Stovner L.J., and Holmen J. Analgesic overuse among subjects with headache, neck, and low-back pain. Neurology 62 (2004) 1540-1544